Trial reportRespiratory research2025
Efficacy and safety of remimazolam-based sedation for intensive care unit patients undergoing fiberoptic bronchoscopy: a single-center prospective randomized controlled study.
Trial report in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe analgesic and sedative strategies during fiberoptic bronchoscopy(FB) in critically ill patients are rarely studied.Remimazolam is a novel sedative whose metabolism is not affected by liver and kidney function.We did a prospective randomized controlled study to compare the efficacy and safety of remimazolam and propofol in sedation therapy for FB patients with liver and kidney dysfunction.
methodsThe study was conducted in the Third Affiliated Hospital of Sun Yat-sen University (China) from September 2021 to December 2022. 120 adult patients were included, randomly assigned to two groups (the remimazolam or the propofol group) and achieved moderate sedation and successful bronchoscopy.The operation process of FB and changes in liver and kidney function indicators after FB operation were all recorded.
resultsAll patients successfully completed the FB with no difference between the two groups in terms of the median time to achieve the target sedation depth (5 min vs. 5 min, P > 0.05).The remimazolam group required fewer sedation rescues (3.33% vs. 16.67%, P = 0.03). The incidence of hypotension was significantly lower in the remimazolam group (3.33% vs. 20%, P = 0.01).The median time to return to the pre-test level of consciousness was similar between the two groups (7 min vs. 7 min, P > 0.05). There was no significant difference in liver and kidney function indexes between the two groups (P > 0.05).
conclusionsRemimazolam demonstrated a sedative effect that was not inferior to propofol.
trial registrationThe Chinese Clinical Trial Registry (chiCTR.gov):No. ChiCTR2100050181, Date of registration: August 15, 2021. The date of enrolment of the first research participant was September 15,2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.